SCHEDULE 13G/A: Wellington Management Group Discloses 11.8% Stake in Rocket Pharmaceuticals

Wellington Management Group LLP and its affiliates have filed an amended Schedule 13G, reporting beneficial ownership of 11.8% of Rocket Pharmaceuticals, Inc.'s common stock as of March 31, 2025.

Summary

• Wellington Management Group LLP and its affiliated entities (Wellington Group Holdings LLP, Wellington Investment Advisors Holdings LLP, and Wellington Management Company LLP) have filed an Amendment No. 4 to Schedule 13G.
• As of March 31, 2025, the group beneficially owns an aggregate of 12,626,491 shares of Rocket Pharmaceuticals, Inc. common stock.
• This represents 11.8% of the total outstanding common stock of Rocket Pharmaceuticals, Inc.
• The reporting persons hold shared voting power over 11,653,331 shares and shared dispositive power over 12,626,491 shares.
• The shares are held for clients of Wellington Investment Advisers in the ordinary course of business, not for the purpose of changing or influencing control of Rocket Pharmaceuticals.
• Vanguard Health Care Fund is noted as a client that may have an interest in more than 5% of the class, though specific details are not provided beyond its name.

Sentiment

Score: 5

Explanation: The document is a routine beneficial ownership filing (Schedule 13G) and does not contain information that inherently indicates positive or negative sentiment regarding the issuer's performance or prospects. It is a neutral, factual report of an institutional investor's stake.

Positives

• Wellington Management Group, a prominent investment firm, maintains a significant 11.8% stake in Rocket Pharmaceuticals, indicating continued confidence in the company.

Negatives

• No negative information regarding Rocket Pharmaceuticals, Inc.'s operations or financial performance was disclosed in this beneficial ownership filing.

Risks

• The filing itself does not detail specific operational or financial risks for Rocket Pharmaceuticals, Inc.
• The reporting persons certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Future Outlook

This Schedule 13G filing does not provide any forward-looking statements or guidance regarding Rocket Pharmaceuticals, Inc.'s future outlook.

Management Comments

• No direct management comments from Rocket Pharmaceuticals, Inc. were included in this beneficial ownership filing.

Industry Context

This filing reflects ongoing institutional investor activity within the biotechnology and pharmaceutical sectors, where specialized funds like Vanguard Health Care Fund maintain significant positions in companies like Rocket Pharmaceuticals, Inc., which are typically focused on developing novel therapies.

Comparison to Industry Standards

• This beneficial ownership filing does not contain information suitable for comparison to industry standards or specific comparable companies/projects.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder's stake, which can influence market perception and liquidity.
• Investment Professionals: Offers insight into the holdings of major investment firms, potentially signaling confidence or strategic positioning.

Next Steps

• No specific future actions, events, or milestones for Rocket Pharmaceuticals, Inc. were mentioned in this filing.

Key Dates

Keywords

Rocket Pharmaceuticals, Wellington Management, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, RPID